H.C. Wainwright lowered the firm’s price target on Allogene Therapeutics to $9 from $10 and keeps a Buy rating on the shares. The analyst cites dilution following the Q1 report for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target raised to $4.60 from $4.40 at Stifel
- Allogene Therapeutics 37.93M share priced at $2.90
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics reports Q1 EPS (38c), consensus (41c)
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update